At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 79 enrolled
Drug / intervention
Sirolimusdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of High- vs Low-Dose Sirolimus in Patients With Kaposiform Hemangioendothelioma: A Trial Protocol
In Brief
A Phase 2 clinical trial evaluating Sirolimus for Kaposiform Hemangioendothelioma. Completed, enrolled 79 participants across 1 site.
Detailed Summary
The purpose of this study is to compare the efficacy and safety of different concentration gradients of sirolimus in the treatment of Kaposiform hemangioendothelioma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKaposiform Hemangioendothelioma
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartFeb 2021
First PostedMar 2021
Primary CompletionAug 2023
TodayJul 2026
First PostedMar 1, 2021
Enrollment StartFeb 17, 2021
Primary CompletionAug 10, 2023
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 5.3 years ago
Interventions
Sirolimusdrug
Use of different doses of the same drug